

Table I. Patient characteristics (N=94).

Characteristic		Value
Gender, n (%)	Male	68 (72)
	Female	26 (28)
Age, years	Median (range)	63 (33-79)
T-Stage, n (%)	1	18 (19)
	2	28 (30)
	3	20 (21)
	4	28 (30)
N-Stage, n (%)	0	10 (10)
	1	11 (12)
	2	64 (68)
	3	9 (10)
Clinical stage, n (%)	IIA	2 (2)
	IIB	1 (1)
	IIIA	62 (66)
	IIIB	29 (31)
Histology, n (%)	Adenocarcinoma	43 (46)
	Squamous cell carcinoma	33 (35)
	Undifferentiated carcinoma	2 (2)
	Non-small-cell carcinoma	15 (16)
	Class V	1 (1)
Smoking history, n (%) ^a	Never	15 (17)
	Former	27 (30)
	Current	47 (53)
ECOG-PS, n (%) ^a	0	58 (62)
	1	34 (37)
	2	1 (1)
Location, n (%)	Upper lobe	65 (69)
	Middle lobe	8 (9)
	Lower lobe	21 (22)
Laterality, n (%)	Right	54 (57)
	Left	40 (43)
FEV1, l ^a	Median (range)	2.49 (1.37-4.17)
Chemotherapy, n (%)	Cisplatin-docetaxel	86 (92)
	Carboplatin-paclitaxel	3 (3)
	Cisplatin-vinorelbine	1 (1)
	Tegafur-gimeracil-oteracil	4 (4)
Radiation dose, Gy	Median (range)	46 (40-60)
Surgery, n (%)	Partial resection	1 (1)
	Lobectomy	77 (82)
	Bilobectomy	11 (12)
	Pneumonectomy	5 (5)
V5, %	Median (range)	30.5 (13.8-57.4)
V20, %	Median (range)	19.4 (6.7-38.5)
Mean lung dose, Gy	Median (range)	9.8 (3.6-19.1)
Body mass index, kg/m ^{2a}	Median (range)	21.6 (14.5-31.2)
Skeletal muscle index, cm ² /m ²	Median (range)	46.5 (29.7-67.0)
Psoas muscle index, cm ² /m ²	Median (range)	6.0 (2.7-10.4)
Visceral adipose index, cm ² /m ²	Median (range)	31.4 (0.6-80.0)
Subcutaneous adiposity index, cm ² /m ²	Median (range)	36.7 (1.4-134.7)
Visceral-to-subcutaneous fat ratio	Median (range)	0.8 (0.1-2.2)

ECOG-PS: Eastern Cooperative Oncology Group performance status; FEV1: forced expiratory volume in 1 second; V5: lung volume percentage receiving >5 Gy; V20: lung volume percentage receiving >20 Gy. ^aThese data have missing values.